REGN Options Turn Defensive Two Days Before Q3 Print

Regeneron Pharmaceuticals reports Q3 results on October 30, and the most notable shift since last week's broadly bullish coverage is in options: the put/call ratio has climbed to 0.90, almost 2.8 standard deviations above its 20-day average of 0.84, a swing that marks the most defensive options posture the stock has seen in recent weeks. The stock itself has gained about 1% over the past week to $816.10, a quieter move than the 4%-plus median advance across its closest biotech peers.

The hedging in options is the sharpest change from the picture painted a week ago. Earlier coverage noted the PCR had dropped to call-heavy territory. That has reversed: put demand is now running well above the recent norm, even as the broader backdrop has not deteriorated. Short interest remains low at 2.2% of the free float and has edged up only marginally week-on-week, continuing a trend that has seen bears cover roughly 15% of their positions over the past month. Borrow availability remains at the maximum reading the data captures, and cost to borrow is 0.35%, low enough that the lending market carries no squeeze pressure whatsoever.

The analyst picture remains constructive, though a notable split has opened between the conviction buyers and the neutrals. UBS upgraded to Buy two weeks ago with a $978 target, and TD Cowen raised its target to $980. Morgan Stanley, by contrast, kept its Equal-Weight rating with a target of $779, below the current price. The consensus mean of $867 sits about 6% above where the stock is trading. On one side, the bull case rests on Dupixent's continued expansion across multiple approved indications and the Eylea HD mix shift supporting margins. On the other, bears point to biosimilar risk on the core Eylea franchise and the fianlimab phase III miss in first-line metastatic melanoma, which narrowed the near-term pipeline story.

One real-economy data point is worth noting without overstating. Medicaid dollars reimbursed for Regeneron drugs have fallen for three consecutive quarters, according to CMS data, and were down 26% year-on-year in the quarter ending January 2026. Medicaid is a partial window on the business; it does not map directly to total revenues. No dataset covering Regeneron has been measured to lead the figures the October 30 print will report, so this reads as context on payer mix pressure rather than a signal about the quarter.

Thursday's print will test whether Dupixent's growth trajectory and the Eylea HD ramp are moving fast enough to offset the biosimilar drag on legacy Eylea and the Medicaid reimbursement trend, and whether the pipeline, after the fianlimab setback, still carries enough near-term value to justify the gap between the current price and the more optimistic analyst targets.